Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilar Diplomacy By Other Means: GPhA CEO Calls Out Amgen Guest

This article was originally published in The Pink Sheet Daily

Executive Summary

During speech to the group’s annual meeting, GPhA President Ralph Neas says he is disappointed that Amgen, which is among the firms attending the gathering, is pushing biosimilar substitution restrictions in state legislatures.

You may also be interested in...



If You Can't Beat 'Em … Hire 'Em? PhRMA Exec Is New GPhA CEO

Chip Davis still believes in innovation, but now must balance that with affordability in new role leading the generic association.

GPhA’s Goals For 2013: Smooth GDUFA Implementation, Workable Biosimilar Pathway

The generic drug trade association’s cross-cutting priorities are the result of an extensive strategic planning process, CEO Ralph Neas says; the group is planning outreach to Congress and the executive branch to highlight the role generic drugs can play in helping to address the nation’s fiscal problems.

Draft Guidances For 2013 Will Grapple With Biosimilars, Track and Trace, Compounding

FDA’s Center for Drug Evaluation and Research plans to publish more than 50 new and revised draft guidances this calendar year.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS075298

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel